TY - JOUR
T1 - Effect of a contraceptive pill containing estradiol valerate and dienogest (E2V/DNG) in women with menstrually-related migraine (MRM)
AU - Nappi, Rossella E.
AU - Terreno, Erica
AU - Sances, Grazia
AU - Martini, Ellis
AU - Tonani, Silvia
AU - Santamaria, Valentina
AU - Tassorelli, Cristina
AU - Spinillo, Arsenio
PY - 2013/9
Y1 - 2013/9
N2 - Background Combined hormonal contraception might worsen migraine in sensitive women, especially during the free-hormone interval, and raise concerns about the vascular risk. The characteristics of a contraceptive pill containing estradiol valerate/dienogest (E2V/DNG) might be of potential benefit in women with menstrually related migraine (MRM) who choose to use oral contraception for birth control. Study design This was a prospective diary-based pilot study. Thirty-two women (age > 35 years) [n= 18 who had never used combined oral contraceptives (COCs) and n= 14 who had previously used COCs] diagnosed with MRMs according to the International Headache Society criteria were included. During the observational period, women filled in a diary with the clinical characteristics of migraine attacks. After a three-cycle run-in period, each subject received a COC containing E2V/DNG (Qlaira®/Natazia®; Bayer HealthCare, Berlin, Germany) administered using an estrogen step-down and progestogen step-up approach. Follow-up evaluations were scheduled at the last cycle of run-in and at the third and sixth cycles of treatment. Results The number of migraine attacks was significantly reduced at the third (p
AB - Background Combined hormonal contraception might worsen migraine in sensitive women, especially during the free-hormone interval, and raise concerns about the vascular risk. The characteristics of a contraceptive pill containing estradiol valerate/dienogest (E2V/DNG) might be of potential benefit in women with menstrually related migraine (MRM) who choose to use oral contraception for birth control. Study design This was a prospective diary-based pilot study. Thirty-two women (age > 35 years) [n= 18 who had never used combined oral contraceptives (COCs) and n= 14 who had previously used COCs] diagnosed with MRMs according to the International Headache Society criteria were included. During the observational period, women filled in a diary with the clinical characteristics of migraine attacks. After a three-cycle run-in period, each subject received a COC containing E2V/DNG (Qlaira®/Natazia®; Bayer HealthCare, Berlin, Germany) administered using an estrogen step-down and progestogen step-up approach. Follow-up evaluations were scheduled at the last cycle of run-in and at the third and sixth cycles of treatment. Results The number of migraine attacks was significantly reduced at the third (p
KW - Bleeding
KW - Dienogest
KW - Dysmenorrhea
KW - Estradiol valerate
KW - Hormonally associated headaches
KW - Migraine without aura
UR - http://www.scopus.com/inward/record.url?scp=84883451417&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883451417&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2013.02.001
DO - 10.1016/j.contraception.2013.02.001
M3 - Article
C2 - 23453784
AN - SCOPUS:84883451417
VL - 88
SP - 369
EP - 375
JO - Contraception
JF - Contraception
SN - 0010-7824
IS - 3
ER -